RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - Phase 3 Study Ultragenyx Pharmaceutical Inc. announced that the first patient has been dosed in its pivotal Phase 3 Aspire study for GTX-102, aimed at treating Angelman syndrome, which will involve about 120 children aged 4 to 17.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC